Literature DB >> 16278672

Deregulation of homologous recombination DNA repair in alkylating agent-treated stem cell clones: a possible role in the aetiology of chemotherapy-induced leukaemia.

L J Worrillow1, J M Allan.   

Abstract

Chemotherapeutic regimes involving alkylating agents, such as methylators and crosslinking nitrogen mustards, represent a major risk factor for acute myeloid leukaemia. A high frequency of microsatellite instability and evidence of MSH2 loss in alkylating chemotherapy-related acute myeloid leukaemia (t-AML) suggests that DNA mismatch repair (MMR) dysfunction may be an initiating event in disease evolution. Subsequent accumulation of secondary genetic changes as a result of DNA MMR loss may ultimately lead to the gross chromosomal abnormalities seen in t-AML. Homologous recombination repair (HRR) maintains chromosomal stability by the repair of DNA double-strand breaks, and is therefore a possible target for deregulation in MMR dysfunctional t-AML. In order to test this hypothesis Msh2- proficient and -deficient murine embryonic stem (ES) cells were used to examine the effects of MMR status and methylating agent treatment on cellular expression of DNA double-strand break repair genes. HRR gene expression was significantly deregulated in Msh2 null ES cell clones compared to wild-type clones. Furthermore, some Msh2 null clones expressed high levels of Rad51 specifically, a critical component of HRR. Such Rad51 superexpressing clones were also observed when expression was determined in monocytic myeloid cells differentiated from ES cells. A deregulated HRR phenotype could be partially recapitulated in MMR-competent wild-type cells by treatment with the methylating agent, N-methyl-N-nitrosourea. Furthermore, treatment with melphalan, a leukaemogenic DNA crosslinking chemotherapy nitrogen mustard predicted to elicit HRR, selected against cells with deregulated HRR. These data suggest a t-AML mechanism whereby DNA MMR loss promotes the emergence of HRR gene superexpressing clones, with concomitant chromosomal instability. However, melphalan selection against clones with deregulated HRR suggests that persistence and expansion of unstable clones may require additional genetic alterations that promote cell survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278672     DOI: 10.1038/sj.onc.1209208

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Methylating agents and DNA repair responses: Methylated bases and sources of strand breaks.

Authors:  Michael D Wyatt; Douglas L Pittman
Journal:  Chem Res Toxicol       Date:  2006-12       Impact factor: 3.739

Review 2.  Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors.

Authors:  Smita Bhatia
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-10       Impact factor: 4.254

3.  Therapy-related myelodysplasia and acute myeloid leukemia.

Authors:  Smita Bhatia
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

4.  Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.

Authors:  Artur Slupianek; Yashodhara Dasgupta; Shu-Yue Ren; Ewa Gurdek; Milene Donlin; Margaret Nieborowska-Skorska; Fabrice Fleury; Tomasz Skorski
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

Review 5.  Subsequent malignant neoplasms after hematopoietic cell transplantation.

Authors:  Gerard Socié; K Scott Baker; Smita Bhatia
Journal:  Biol Blood Marrow Transplant       Date:  2012-01       Impact factor: 5.742

6.  Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility.

Authors:  Jeffrey A Knight; Andrew D Skol; Abhijit Shinde; Darcie Hastings; Richard A Walgren; Jin Shao; Thelma R Tennant; Mekhala Banerjee; James M Allan; Michelle M Le Beau; Richard A Larson; Timothy A Graubert; Nancy J Cox; Kenan Onel
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

Review 7.  Molecular biology of therapy-related leukaemias.

Authors:  Melanie Joannides; David Grimwade
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

Review 8.  Review of risk factors of secondary cancers among cancer survivors.

Authors:  Charlotte Demoor-Goldschmidt; Florent de Vathaire
Journal:  Br J Radiol       Date:  2018-09-12       Impact factor: 3.039

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.